TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

71 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    📍 Mayo Clinic in Arizona · Scottsdale, AZ · +4 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

    Studying how blood vessel and nerve control during exercise works in people with chronic kidney

    📍 Emory Clinic · Atlanta, GA · +1 more US site · Get directions →

    The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).

    ✓ Study care freePhase 2Ages 40–75Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →

    This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

    Testing whether an experimental medicine is safe and works for eczema

    📍 Northridge Clinical Trials · Northridge, CA · +3 more US sites · Get directions →

    The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

    Testing a 12-week diabetes medicine combination in kidney transplant patients with kidney disease

    📍 Toronto General Hospital · Toronto, Ontario · Get directions →

    The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Cardamom and Topical Roseomonas in Atopic Dermatitis

    Testing cardamom and a skin-applied germ to treat eczema

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems.

    ✓ Study care freePhase 2Ages 2–100Learn more →
  • Kidney disease

    Acute Equol Supplementation and Vascular Function in Women With and Without CKD

    Testing whether taking equol affects blood vessel function in women with or without CKD

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50–69WomenLearn more →
  • Kidney disease

    📍 SouthCoast Research Center, Inc. · Miami, FL · +1 more US site · Get directions →

    The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression.

    ✓ Study care freePhase 1Ages 35–75Learn more →
  • Kidney disease

    Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.

    Testing whether exercise during dialysis and creatine help people with chronic kidney disease

    📍 IMSS-Bienestar State Haemodialysis Centre · Colima, Coliima · Get directions →

    This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. The study will compare the independent and combined effects of these interventions over an 8-week period to determine their potential benefits in this patient population.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

    Testing the long-term safety and effects of a drug in people with eczema

    📍 Investigational Site · Fountain Valley, CA · +21 more US sites · Get directions →

    This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

    Testing whether daily soy milk affects liver disease in children with fatty liver

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.

    ✓ Study care freePhase 2Ages 5–12Learn more →
  • Eczema / atopic dermatitis

    A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

    Testing a medicine for moderate to severe eczema, compared with a placebo

    📍 Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute · Phoenix, AZ · +39 more US sites · Get directions →

    This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

    ✓ Study care freePhase 2Ages 18–100Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

    Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Kidney disease

    A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

    Testing safety and effects on urine protein in adults with APOL1 kidney disease

    📍 Research Site · Decatur, AL · +39 more US sites · Get directions →

    This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

    ✓ Study care freePhase 2Ages 18–68Learn more →
  • Eczema / atopic dermatitis

    A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    Testing different doses of a medicine versus placebo for eczema

    📍 Inmagene Site 1 · Lancaster, CA · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Fatty liver disease (NASH/MASH)

    Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    Testing how SGLT2 inhibitors work for fatty liver disease in obese teens

    💵 May compensate

    📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    ✓ Study care freePhase 2Ages 16–20Learn more →
  • Eczema / atopic dermatitis

    Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

    Testing how different doses of soquelitinib work for moderate to severe atopic dermatitis

    📍 Corvus Clinical Trials · South San Francisco, CA · Get directions →

    The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

    Testing colchicine for safety and effects in people with chronic kidney disease

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

    ✓ Study care freePhase 2Ages 21–80Learn more →
  • Eczema / atopic dermatitis

    Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

    Testing a daily medicine for eczema and hair loss in people with Down syndrome

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks.

    ✓ Study care freePhase 2Ages 12+Learn more →
  • Eczema / atopic dermatitis

    A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

    Checking the long-term safety and effects of an eczema medicine in people who previously studied it

    📍 Hamilton Research, LLC · Alpharetta, GA · +2 more US sites · Get directions →

    This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

    Testing a GE xenokidney transplant in people with ESRD for safety and effectiveness

    📍 Northwestern Memorial Hospital · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Kidney disease

    Bone in CKD Alkali Response (BICARb Pilot Trial)

    Testing whether potassium citrate improves bone health in people with chronic kidney disease

    📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →

    The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.

    ✓ Study care freePhase 2Ages 5–100Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    Testing efimosfermin in people with MASH-related compensated cirrhosis

    💵 May compensate

    📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Kidney disease

    Testosterone Treatment in Men With Chronic Kidney Disease

    Testing an oral testosterone medicine to raise testosterone in men with chronic kidney disease

    📍 Saint Louis Univeristy · St Louis, MO · Get directions →

    This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).

    ✓ Study care freePhase 2Ages 18–85MenLearn more →
  • Fatty liver disease (NASH/MASH)

    Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

    Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and

    💵 May compensate

    📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →

    This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

    Testing a new kidney tissue transplant to treat end-stage kidney disease

    📍 New York University Langone Health · New York, NY · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Kidney disease

    Breakthrough - T1DM and Chronic Kidney Disease

    Testing an experimental treatment of Tegoprubart plus islet cells for diabetes and chronic kidney

    📍 The University of Chicago · Chicago, IL · Get directions →

    Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA).

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Eczema / atopic dermatitis

    A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing how camoteskimab works in adults with moderate to severe eczema

    📍 AllerVie Clinical Research · Birmingham, AL · +32 more US sites · Get directions →

    This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 Physioseq, LLC /ID# 267266 · Sacramento, CA · +1 more US site · Get directions →

    Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing repeat under-the-skin doses of FB825 for adult eczema

    📍 First OC Dermatology · Fountain Valley, CA · +5 more US sites · Get directions →

    This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Kidney diseaseCrohn's / ulcerative colitis (IBD)

    Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    Comparing patient preferences for skin injections vs IV for immune therapy in kidney disease or

    📍 UPMC Hillman Cancer Center · Pittsburgh, PA · Get directions →

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    REgulatory T Cell Therapy to Achieve Immunosuppression REduction

    Testing a cell therapy to lower the chance of kidney transplant rejection

    📍 Mayo Clinic in Arizona · Phoenix, AZ · +2 more US sites · Get directions →

    The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. Enrolled subjects will be randomized to one of 2 study arms: Arm 1 subjects will receive standard of care immunosuppression Arm 2 subjects will receive initial standard of care (SOC) immunosuppression and a single infusion of TRK-001.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 ALS Global · Irving, TX · Get directions →

    This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • High cholesterol

    A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

    Testing how safe and well weekly injections of alirocumab work for high cholesterol in adults

    📍 Anaheim Clinical Trials · Anaheim, CA · +29 more US sites · Get directions →

    This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Milk Thistle Clinical Trial in Pediatric NAFLD

    Testing milk thistle for children with fatty liver disease

    💵 May compensate

    📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →

    Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.

    ✓ Study care freePhase 2Ages 9–22Learn more →
  • Fatty liver disease (NASH/MASH)

    Digoxin In NASH (CODIN)

    Testing digoxin for people with metabolic fatty liver inflammation

    📍 Yale New Haven Health · New Haven, CT · +1 more US site · Get directions →

    Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • High blood pressureKidney disease

    Equol and Vascular Function in Women With Chronic Kidney Disease

    Testing whether equol affects blood vessel function in women with chronic kidney disease

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50+WomenLearn more →
  • Kidney disease

    A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

    Testing a medicine given at fixed doses for high phosphate in adults on hemodialysis

    📍 R1 Therapeutics Clinical Trial Site · Huntsville, AL · +22 more US sites · Get directions →

    This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

    Testing a 1-year weight-loss medicine to slow kidney cyst growth in adults with ADPKD

    📍 University of Colorado - Anschutz Medical Campus · Aurora, CO · Get directions →

    The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Kidney disease

    Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

    Testing orellanine in kidney cancer patients on chronic hemodialysis to see if it is safe and may

    📍 Stanford · Palo Alto, CA · +2 more US sites · Get directions →

    A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

    Comparing doses of a new medicine to see effects on kidney damage in chronic kidney disease

    📍 N America Res Inst - San Dimas · San Dimas, CA · +17 more US sites · Get directions →

    The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

    Testing medicines that lower ANGPTL3 in adults with diabetic kidney disease

    📍 Apogee Clinical Research, LLC · Huntsville, AL · +39 more US sites · Get directions →

    This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Eczema / atopic dermatitis

    📍 Atd002 52021 · Oceanside, CA · +19 more US sites · Get directions →

    The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing a daily medicine for eczema severity in adults over 12 weeks

    📍 Enveda Investigative Site · Birmingham, AL · +22 more US sites · Get directions →

    The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    Testing resmetirom in people with MASH-related liver scarring after liver transplant

    💵 May compensate

    📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →

    A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Kidney disease

    Safety and Efficacy of Empagliflozin in Hemodialysis

    Testing whether empagliflozin is safe and effective for people starting hemodialysis

    📍 Brigham and Women's Hospital · Boston, MA · +1 more US site · Get directions →

    A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

    Testing two medicines for safety and effects in people with eczema

    📍 Allervie Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Effects of Treatments on Atopic Dermatitis

    Testing treatments for eczema (atopic dermatitis)

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.

    ✓ Study care freePhase 2Ages 2–50Learn more →
  • Kidney disease

    Neurovascular Transduction During Exercise in Chronic Kidney Disease

    Studying why people with chronic kidney disease have low exercise capacity and high blood pressure

    📍 Emory University Hospital Midtown · Atlanta, GA · +2 more US sites · Get directions →

    The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • High cholesterolLupus (SLE)

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

    Testing certolizumab added to usual treatment to improve pregnancy in lupus and antiphospholipid

    📍 Hospital for Special Surgery · New York, NY · +1 more US site · Get directions →

    This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.

    ✓ Study care freePhase 2Ages 18–40WomenLearn more →
  • Kidney disease

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

    Testing Envarsus XR versus twice-daily tacrolimus in kidney transplant rejection and blood immune

    📍 Deepa Valvi · Lexington, KY · Get directions →

    This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end stage renal disease listed for primary solitary kidney transplant.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Type 2 diabetesKidney disease

    Uric Acid Lowering Trial in Youth Onset T2D

    Testing how lowering uric acid affects young people with type 2 diabetes and kidney disease

    📍 Children's Hospital Colorado · Aurora, CO · Get directions →

    Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D). In fact, 50% of males with youth-onset T2D have serum uric acid (SUA) greater than 6.8 mg/dl.

    ✓ Study care freePhase 2Ages 18–25MenLearn more →
  • Kidney diseaseDepression

    Combination of Novel Therapies for CKD Comorbid Depression

    Testing whether treating major depression improves outcomes in people with chronic kidney disease

    📍 Stony Brook University Medical Center · Stony Brook, NY · +3 more US sites · Get directions →

    The overall goal of the study is to determine if treatment of a Major Depressive Disorder (MDD) improves the outcomes of patients with chronic kidney disease (CKD). We showed that MDD is present in 25% of CKD patients and independently associated with progression to End-Stage Kidney Disease, hospitalization, and death.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Low-Dose Pioglitazone in Patients With NASH (AIM 2)

    Testing a low-dose diabetes medicine to see effects on liver changes in NASH

    💵 May compensate

    📍 University of Florida · Gainesville, FL · Get directions →

    To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

    ✓ Study care freePhase 2Ages 21–75Learn more →
  • Kidney disease

    Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

    Testing a treatment for people with pulmonary hypertension and severe kidney problems, with or

    📍 Clinical Trial Site · San Francisco, CA · +3 more US sites · Get directions →

    The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

    ✓ Study care freePhase 2Learn more →
  • Kidney disease

    Ferric Citrate and Chronic Kidney Disease in Children

    Testing whether ferric citrate changes a kidney hormone in children with CKD

    📍 University of California, Los Angeles · Los Angeles, CA · +17 more US sites · Get directions →

    We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo.

    ✓ Study care freePhase 2Ages 6–18Learn more →
  • Kidney disease

    Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

    Testing sodium bicarbonate on muscle energy use in people with chronic kidney disease

    📍 University of California Davis Health · Sacramento, CA · +1 more US site · Get directions →

    Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability.

    ✓ Study care freePhase 2Ages 21–85Learn more →
  • Showing the first 60 of 71. Add filters or a location to narrow down.